₹166.00
−2.41%NSE close, 16 Nov 2026
+17.73%
CURIS LIFESCIENCES is a small cap company, listed on NSE SME under the symbol CURIS. At ₹166.00 a share, the market values the whole company at ₹134 crore. NSE SME is the exchange's platform for small and medium companies, which report their results every half year.
In FY26, it reported sales of ₹61 crore and a net profit of ₹7 crore, an operating margin of 18.4%.
The market values the company at 19.6 times its profit over the last twelve months and 2.61 times its book value; its return on equity is 13.3% and its borrowings are 0.39 times its equity.
Promoters hold 68.03% of the shares. Foreign institutions hold 1.05%, and domestic institutions, mutual funds among them, 4.63%.
Listed on NSE SME, the platform for small and medium companies: its shares trade in large lots and often thinly, so the price can move sharply on a few trades, and companies file results every half year.
₹ crore. Consolidated figures where the company filed them, standalone otherwise (marked S).
| Line | 6M to Sep 2025 S | 6M to Mar 2026 S | 6M to Sep 2026 |
|---|---|---|---|
| Sales | 27.9 | 32.7 | 37.0 |
| Expenses | 21.9 | 27.6 | 30.9 |
| Operating profit | 6.0 | 5.1 | 6.2 |
| Operating margin | 21.5% | 15.7% | 16.7% |
| Other income | 0 |
Standalone andconsolidated financials results for the half year ended on 30th September, 2026
The standalone and consolidated financial results for the half year ended September 30, 2026.
Has informed regarding Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Quarter and year ended on September 30, 2026
| 0.5 |
| Interest | 0.4 | 0.7 | 0.6 |
|---|
| Depreciation | 0.3 | 0.4 | 0.4 |
|---|
| Profit before tax | 5.2 | 4.3 | 5.7 |
|---|
| Tax | 1.0 | 1.6 | 1.5 |
|---|
| Net profit | 4.2 | 2.7 | 4.1 |
|---|
| EPS (₹) | 7.10 | 4.01 | 5.76 |
|---|
₹ crore, financial years to March.
| Line | FY26 S |
|---|---|
| Sales | 60.6 |
| Expenses | 49.5 |
| Operating profit | 11.1 |
| Operating margin | 18.4% |
| Other income | 0.3 |
| Interest | 1.1 |
| Depreciation | 0.7 |
| Profit before tax | 9.6 |
| Tax | 2.7 |
| Net profit | 6.9 |
| EPS (₹) | 10.26 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY26 | 6M to Sep 2026 |
|---|---|---|
| From operations | −16.4 | −0.2 |
| From investing | −1.6 | −2.4 |
| From financing | 20.9 | −0.4 |
| Spent on fixed assets | −1.8 | −2.6 |
| Free cash flow | −18.2 | −2.8 |
Margins, returns, debt, tax and cash.
| Line | FY26 |
|---|---|
| Net margin | 11.4% |
| Operating margin | 18.4% |
| Return on equity | 14.6% |
| Return on capital employed | 15.5% |
| Return on assets | 8.5% |
| Debt to equity | 0.46 |
| Interest coverage | 9.40 |
| Debt to assets | 0.26 |
| Current ratio | 2.52 |
| Quick ratio | 1.28 |
| Cash ratio | 0.12 |
| Asset turnover | 0.74 |
| Fixed asset turnover | 5.01 |
| Inventory turnover | 1.20 |
| Receivables turnover | 5.40 |
| Gross margin | 30.9% |
| Cash from operations to profit | -237.0% |
| Effective tax rate | 27.7% |
A copy Srutinizers report of 10th Annual General Meeting held on September 29, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of 10thAnnual General Meeting held on September 29, 2026.
Notice of Annual General Meeting to be held on September 29, 2026
Outcome of Board Meeting held on September 07, 2026.
Cessation of Mr Nikhil Purohit as Company Secretary & Compliance Officer of the company w.e.f. September 03, 2026.
Joint venture agreement entered into by the company with CUROSUN PHARMACEUTICAL NIG LTD (Nigerian Company) by acquiring 49.95% stake of such company.
Has informed regarding Non-Applicability of the Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the Quarter and year ended on June 30, 2026
Comments of board on the fine levied by the National Stock Exchange (NSE Limited)
Appointment of Mr Devabhai Hamirbhai Jadeja as Non- Executive Independent Director of the company w.e.f. July 13, 2026.
The Exchange had sought clarification from Curis Lifesciences Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the…